Increasing the efficacy of tumor cell vaccines by enhancing cross priming
Cancer Letters, 08/08/2012
Andersen BM et al. – Tumor cell–based vaccines have been employed in hundreds of clinical trials to date and offer several advantages over subunit and peptide vaccines. However, tumor cell–based vaccines, often aimed at cross priming tumor–reactive CD8 T cells, have shown modest success in clinical trials. A synthesis of recent findings on tissue culture conditions, cell death, and dendritic cell activation reveals promising new avenues for clinical investigation.